

# Danyan Xu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8192610/publications.pdf>

Version: 2024-02-01

19  
papers

281  
citations

1039406

9  
h-index

940134

16  
g-index

22  
all docs

22  
docs citations

22  
times ranked

371  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Enhanced External Counterpulsation on Platelet Aggregation in Patients with Coronary Heart Disease. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 263-269.	1.3	1
2	New insights into the roles of glucocorticoid signaling dysregulation in pathological cardiac hypertrophy. <i>Heart Failure Reviews</i> , 2022, 27, 1431-1441.	1.7	4
3	Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 467-477.	1.3	18
4	Circular RNA in cardiovascular disease: Expression, mechanisms and clinical prospects. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 1817-1824.	1.6	39
5	Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis. <i>Medicine (United States)</i> , 2021, 100, e24579.	0.4	10
6	Advances in the mechanism and treatment of mitochondrial quality control involved in myocardial infarction. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7110-7121.	1.6	3
7	Direct Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-analysis. <i>Drugs</i> , 2021, 81, 2003-2016.	4.9	2
8	Sex differences in survival after out-of-hospital cardiac arrest: a meta-analysis. <i>Critical Care</i> , 2020, 24, 613.	2.5	42
9	Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. <i>Cardiovascular Diabetology</i> , 2020, 19, 33.	2.7	26
10	Stable coronary artery disease and endothelial progenitor cells. <i>International Journal of Cardiology</i> , 2018, 260, 18.	0.8	2
11	Soluble epoxide hydrolase inhibitors might prevent ischemic arrhythmias via microRNA-1 repression in primary neonatal mouse ventricular myocytes. <i>Molecular BioSystems</i> , 2017, 13, 556-564.	2.9	9
12	Soluble epoxide hydrolase inhibitors, t-AUCB, regulated microRNA-1 and its target genes in myocardial infarction mice. <i>Oncotarget</i> , 2017, 8, 94635-94649.	0.8	14
13	Is sEHi lowering LDL-C by reducing expression of PCSK9 through SREBP2 pathway?. <i>International Journal of Cardiology</i> , 2016, 207, 361-362.	0.8	1
14	The S100A8-serum amyloid A3-LOX-1 cascade in atherosclerotic plaque rupture. <i>International Journal of Cardiology</i> , 2016, 203, 832-833.	0.8	3
15	RKIP corrects impaired beta (2)-adrenergic receptor vasodilatation in hypertension by downregulation of GRK2. <i>International Journal of Cardiology</i> , 2016, 207, 359-360.	0.8	3
16	Aerobic exercise-based rehabilitation affects the activities of progenitor endothelial cells through EETs pathway. <i>Medical Hypotheses</i> , 2015, 85, 1037-1038.	0.8	2
17	A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPAR $\gamma$ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 1298-1304.	0.8	59
18	Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2010, 88, 71-75.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine. <i>Atherosclerosis</i> , 2010, 211, 237-241.	0.4	21